Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXZ9T3)

Drug Name

AC-170 Drug Info

Synonyms

88139-91-7; 5-Bromo-2-hydroxymethylpyridine; (5-Bromopyridin-2-yl)methanol; 2-hydroxymethyl-5-bromopyridine; 5-Bromo-2-(hydroxymethyl)pyridine; (5-bromopyrid-2-yl)methanol; 5-Bromo-2-pyridinemethanol; (5-Bromo-pyridin-2-yl)-methanol; 2-PYRIDINEMETHANOL, 5-BROMO-; 5-BROMOPYRIDINE-2-METHANOL; (5-bromo-2-pyridyl)methanol; (5-bromo-2-pyridyl)methan-1-ol; AC-170; (5-Bromo-pyridin-2-yl)methanol (5-Bromo-2-hydroxymethylpyridine); zlchem 391; PubChem7710; PubChem12387; ACMC-209qrb; AC1NP90H; 5-bromo-2-pyridine methanol; KSC494K9D

Indication

Disease Entry	ICD 11	Status	REF
Allergic conjunctivitis	9A60.02	Phase 3	[1]

Cross-matching ID

PubChem CID: 5200169
CAS Number: CAS 88139-91-7
TTD Drug ID: DMXZ9T3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Histamine H1 receptor (H1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[3]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[4]
Azelastine	DMXTMBJ	Allergic conjunctivitis	9A60.02	Approved	[5]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[6]
Cinnarizine	DM7U5QJ	Meniere disease	AB31.0	Approved	[7]
Diphenhydramine	DMKQTBA	Hyperemesis gravidarum		Approved	[5]
Doxepin	DMPI98T	Anxiety		Approved	[8]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[5]
Epinastine	DMX0K3Q	Allergic conjunctivitis	9A60.02	Approved	[9]
Desloratadine	DM56YN7	Allergic rhinitis	CA08.0	Approved	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02132169) A Multi-Center Study Evaluating the Safety of AC-170 0.24%. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of NicOx SA.
3	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
4	Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
5	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
6	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
7	Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
8	Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
9	Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
10	Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.